Relypsa (RLYP) Has Multiple Banking Relationships
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Wedbush Reiterates Bullish Stance on Relypsa (RLYP) Following Veltassa MoM Acceleration
April 18, 2016 11:47 AM EDTIn a note Friday, Wedbush analyst Liana Moussatos reiterated her Outperform rating and $52 price target on Relypsa, Inc. (NASDAQ: RLYP) after the third full month of Veltassa launch metrics shows month-over-month acceleration.
In March, 1,277 (+57% MoM) new patients started taking Veltassa with a free starter supply, 706 (+102% MoM) outpatient prescriptions were filled, and 201 (+14% MoM) hospital/institution units were sold.
Veltassa's early launch continues to track... More
BTIG Trims Q1 Sales Outlook on Relypsa's (RLYP) Veltassa Following Recent Update; Affirms at 'Buy'
April 15, 2016 2:44 PM EDTBTIG affirms Relypsa, Inc. (Nasdaq: RLYP) with a Buy rating and $45 price target after the company disclosed new patient starts, outpatient prescriptions and... More
Mizuho Weighs in on Relypsa (RLYP) Veltassa Numbers and Latest on M&A
April 15, 2016 9:59 AM EDTMizuho Securities analyst Irina Koffler weighed in on Relypsa, Inc. (NASDAQ: RLYP) following today's Veltassa prescriptions numbers and the latest M&A speculation.
Koffler noted that Veltassa prescriptions sold were in-line with their estimates. "Relypsa released March's Veltassa numbers, and reported 1,277 patients received a free starter supply of Veltassa, 706 retail prescriptions were filled, and 201 hospital packs were sold. In all, a total of 907 prescriptions/units were reimbursed. This compares to our estimates of 1,624 patients receiving the starter kit, 700 retail TRx's... More
